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Metabolic syndrome (MetS) is a primary risk factor for cardiovascular disease and is associated with a proinﬂammatory state.
Here, we assessed the contribution of inﬂammatory and oxidative stress markers towards prediction of MetS. A total of 2316
individuals were recruited in Phase I of the Indian Atherosclerosis Research Study (IARS). Modiﬁed ATPIII guidelines were used
forclassiﬁcationofsubjectswithMetS.Amongtheinﬂammatoryandoxidativestressmarkersstudied,levelsofhsCRP(P<. 0001),
Neopterin (P = .036), and oxLDL (P<. 0001) were signiﬁcantly higher among subjects with MetS. Among the markers we tested,
oxLDL stood out as a robust predictor of MetS in the IARS population (OR 4.956 95% CI 2.504–9.810; P<. 0001) followed by
hsCRP (OR 1.324 95% CI 1.070–1.638; P = .010). In conclusion, oxLDL is a candidate predictor for MetS in the Asian Indian
population.
1.Introduction
Metabolic syndrome (MetS) is a constellation of metabolic
abnormalities that confer increased risk of cardiovascular
disease (CVD) and diabetes mellitus (DM) [1]. The criteria
for the metabolic syndrome have evolved since the original
deﬁnition by the World Health Organization in 1998 [2],
reﬂecting growing clinical evidence and analysis by a variety
of consensus conferences and professional organizations
[3, 4]. The major features of MetS include central obesity,
hypertriglyceridemia, low HDL cholesterol, hyperglycemia,
and hypertension.
The accepted and unifying hypothesis to describe the
pathophysiology of metabolic syndrome is insulin resistance,
caused by a defect in insulin action that is not fully
understood.Freefattyacids(FFAs)arereleasedinabundance
from an expanded atherogenic adipose tissue mass leading
to hyperinsulinemia [5]. Recent evidence indicates that a
proinﬂammatory state is superimposed and contributes to
the insulin resistance produced by excessive FFAs [6, 7].
Adipose tissue-derived macrophages may be the primary
source of proinﬂammatory cytokines [8], and it has been
reported that enhanced secretion of interleukin 6 (IL-6) and
tumor necrosis factor(TNF-α)byadipocytesandmonocyte-
derived macrophages leads to more insulin resistance and
lipolysis of adipose tissue triglyceride stores increasing
circulating levels of FFAs [9]. IL-6 and other cytokines also
enhance hepatic glucose production, VLDL production by
the liver, and insulin resistance in the muscle. Cytokines
and FFAs are also known to increase hepatic production
of ﬁbrinogen and adipocyte production of plasminogen
activator inhibitor 1 (PAI-1) resulting in a prothrombotic
state [5]. Higher levels of circulating cytokines stimulate the
hepatic production of C-reactive protein (CRP) [10]a n d
reduced production of the anti-inﬂammatory and insulin
sensitizing cytokine, adiponectin has been associated with
MetS [11]. Studies using cellular and animal models have
described the role of oxidized LDL in the pathophysiology
of incident MetS [12, 13]. This hypothesis is supported by
population-based prospective human studies. The CARDIA
study found increased incidence of MetS in individuals with
higher circulating levels of ox-LDL with accumulation of2 Cardiology Research and Practice
three of its risk factor constituents: obesity, hyperglycemia
and hypertriglyceridemia [14]. Both oxidative stress and
inﬂammatorystressassociatedwithMetShavebeenfoundto
initiate and propagate atherosclerotic macrovascular disease
[15].
The multitude of risk factors amalgamating into MetS
is increasing in Indians to reach epidemic proportions,
which may present the common ground that enhances
CVD risk in this ethnic group. The peculiar dyslipidemic
obesity phenotype of Asian Indians with higher truncal
and abdominal fat at lean body mass predisposes this
ethnic group to the consequences of a proinﬂammatory and
prothrombotic state [16]. Thus it is appealing to pursue a
comprehensive CAD risk assessment with an understanding
of the association of inﬂammation between MetS. Here, we
assessed the association of inﬂammatory biomarkers with
MetS and their independent ability to predict MetS in the
studied population.
2.MaterialsandMethods
The Indian Atherosclerosis Research Study (IARS) is an
ongoing, family-based epidemiological study investigating
the genetic, conventional and environmental factors asso-
ciated with CAD in Asian Indians living in the Indian
subcontinent. Novel biomarker discovery is a speciﬁc aim
of this study. For the study, families were enrolled from
two Indian cities: Bangalore and Mumbai. Subjects were
recruited through a proband who showed: (i) angiographic
evidence of CAD (males ≤ 60 years and females ≤ 65
years at onset), (ii) a family history of CAD/CVD and, (iii)
underwent therapeutic/surgical treatment at participating
hospitals. Extended family members (both aﬀected and
unaﬀected)wereenrolled,providedtheymettherecruitment
age of 18 or above. Individuals with a history of any
other major illness or concomitant infections were excluded
from the study. Information pertaining to demographics;
life style; anthropometrics; medical history of diabetes,
hypertension and CAD; medication details, and a three-
generation pedigree were recorded for each participant. Fast-
ing sugar levels of >126mg/dl were considered diabetic and,
a systolic/diastolic blood pressure of >140/90mmHg was
considered hypertensive. The study was conducted following
the guidelines deﬁned by the Indian Council of Medical
Research and the Declaration of Helsinki for undertaking
human clinical research. An institutional ethics committee
approved the IARS and voluntary, signed informed consent
was obtained from all participants.
Blood was collected by venipuncture after an overnight
fast and processed using standardized protocols at each
collection site. Blood was centrifuged for 10min at 4◦C,
aliquoted in 0.5–1mL volumes of sodium-citrate plasma,
EDTA plasma and serum, and stored at −80◦C within 2h
of venipuncture. For protein measurements, samples were
thawedoniceandaliquotedintobar-codedEppendorftubes.
The new sample aliquots were refrozen to −80◦C until time
oftestingatwhichpointtheywerethawedoniceagain.Thus,
samples from each collection site were exposed to identical
numbers of freeze-thaw cycles for a given assay ensuring
that sample handling does not contribute to any signiﬁcant
diﬀerences in protein levels.
2.1. Conventional Risk Factors. Serum total cholesterol and
triglyceride were estimated by standard enzymatic analysis
using reagents, standards and controls from Randox Labora-
tories Ltd. (Antrim, UK). The concentration of high-density
lipoprotein (HDL)-cholesterol was estimated after precipi-
tation of non-HDL fractions with a mixture of 2.4mmol/L
phosphotungstic acid and 39mmol/L magnesium chlo-
ride. The concentration of low-density lipoprotein (LDL)-
cholesterol was calculated using the Fridewald formula.
2.2. Measurement of Candidate Biomarkers. The candidate
protein markers of vascular disease were measured in plasma
(EDTA or citrate) or serum using solid-phase immunoas-
says and immunoturbidometric assays with commercially
available reagents. Plasma interleukin (IL) 6 level and
adiponectin was measured by enzyme-linked immunosor-
bent assa, (ELISA) from R & D Systems (Minneapolis,
USA) and plasma hsCRP level was measured using the
Roche latex Tina quant kit (Roche Diagnsotics, Basel,
Switzerland). Levels of secretory phospholipase A2 (sPLA2)
were determined using a sandwich immunometric assay
(Cayman Corporation, Michigan, USA); myeloperoxidase
using the sandwich enzyme immunoassay using kits from
Mercodia (Uppasala, Sweden), neopterin using the enzyme
immunoassay kit from IBL (Hamburg, Germany), oxLDL
using the commercially available sandwich ELISA kit from
Mercodia (Uppasala Sweden) and Leptin using the ELISA
kit from Bio-Line (Bruxelles, Belgium). In the oxLDL
ELISA, murine monoclonal antibody, mAb-4E6 was used as
capture antibody and the second antibody was a peroxidase-
conjugated anti-apolipoprotein B antibody recognizing ox-
LDL bound to the solid phase.
2.3. Quality Control. Our quality control program included
evaluation of intra-assay variations between duplicate sam-
ple measurements and inter-assay variations between inde-
pendent repeat experiments. Sample measurements with
coeﬃcient of variation, CV > 15% were either retested
or excluded from the dataset. The inter-assay CV for the
commercial controls and NHP ranged from 4.9% to 7.0%
for total cholesterol, 6.1% to 7.7% for triglyceride, 7.1% to
12.2% for HDL-cholesterol, 3.3% to 5.2%. The inter-assay
CV for IL-6 relative to NHP was 4.3%; for plasma hsCRP
7.85%; secretory phospholipase A2 (sPLA2) was 5.37%; the
inter-assay CV for NHP and the low and high controls
providedbythemanufactureralongwiththekitrangedfrom
5.99 to 11.8% for neopterin and from 4.4 to 16% for oxLDL.
2.4. Statistical Analysis. SPSS ver. 17.0 statistical packages
wereusedintheanalysis.AP-value< .05wasconsideredsta-
tistically signiﬁcant. The modiﬁed NCEP-ATPIII procedure
was used to classify the IARS cohort into those with/without
MetS based (Table 1). A cross-classiﬁcation of MetS groups
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Table 1: Metabolic syndrome: diagnostic criteria.
Modiﬁed ATPIII criteria WHO criteria
(i) Abdominal density as
deﬁned by waist circumference
cuts oﬀ ≥90cm for men and
≥80cm for women
(ii) BMI cuts oﬀ at >23kg/m2
(iii) Serum TG ≥ 150mg/dl
(1.7mmol/L)
(iv) HDL-C < 40mg/dl in men
(1.03mmol/L) and < 50mg/dl
(1.29mmol/L) in women
(v) Blood pressure ≥130/85
(vi) Fasting blood glucose level
of ≥110md/dl (6.1mmol/L)
(i) Fasting blood glucose level
of ≥110md/dl (6.1mmol/L)
or Diabetic
(ii) WHR of ≥0.89 in men,
>0.81 in women and BMI >
23kg/m2
(iii) Hypertriglyceridemia
with TG > 150mg/dl
(iv) HDL-C <35mg/dl in men
and < 39mg/dl in women
(v) High Blood Pressure
>140/90mmHg or
documented evidence of
anti-hypertensive therapy
Logarithmictransformationwasperformedtonormalize
skewed variables. Both continuous and categorical forms
of the distribution of these variables were used in the
analysis. The retransformed mean and standard error of
the mean (SEM) are shown in tables. Diﬀerences between
continuous variables were assessed using Student’s t-test and
thosebetweencategoricalvariablesusingtheChi-squaretest.
Analysis of covariance was used to test for signiﬁcance after
adjusting for potential confounding variables. Odds ratios
(ORs) and corresponding 95% conﬁdence intervals (CIs)
were calculated using conditional logistic regression analysis.
The Sensitivity, Speciﬁcity and Area under ROC were
calculated for each model to determine its discriminative
capacity. This method tests the diﬀerence between two
models in their estimated probability to correctly classify
“case subject” as “case subject”, and “control subject” in to
a control group. This reveals the prediction ability of the
model. To assess the predictive value of the biomarkers, all
variables were entered into a conditional logistic regression
model (taking into account the gender and age matching),
and cumulative AUC was calculated using the predictive
probability values.
Multinomial Logistic Regression was used to identify the
contribution of the selected biomarkers using odds ratio and
associated conﬁdence interval. The groups 1 and 2 are: no
MetS, and MetS with no CAD and groups 3 and 4 are MetS
groups within CAD group. Multinomial Logistic Regression
is similar to binary logistic regression with no restriction on
the number of dependent variables.
To identify biomarkers that discriminate between MetS
and no MetS groups, and to identify the threshold levels
of these biomarkers for correct classiﬁcation, a two-group
discriminate analysis was used. The linear discriminate
function is an objective statistical method used to obtain
predictive scores based on two or more variables from
group discrimination. The discriminate score is based on
the overall mean values of each of the variables. Individuals
were classiﬁed into one group or the other depending on
whether the score of an individual is lesser or greater than
the predictive score.
3. Results
3.1. Clinical and Demographic Characteristics of IARS Partic-
ipants. The 2005 modiﬁed National Cholesterol Education
Programme Adult Treatment Panel III (NCEP ATP III)
criteria [3] were used to deﬁne MetS in the study population
(Table 1). A total of 2316 individuals were categorized into
two groups of subjects with or without MetS, based on
the presence of a minimum of 3 out of 5 of the deﬁning
risk factors (Table 1). As expected, subjects with MetS had
signiﬁcantly higher systolic blood pressure(BP),diastolic BP,
bodymassindex(BMI),circulatinglevelsoftotalcholesterol,
triglycerides and LDL cholesterol than those without MetS.
Similarly, HDL levels were signiﬁcantly lower in MetS
subjects with signiﬁcantly more diabetics & hypertensive.
There was no diﬀerence in the number of smokers in the
two groups canceling the oxidative and inﬂammatory stress
due to smoking on either group of subjects (Table 2). As
anticipated subjects with MetS had signiﬁcantly higher levels
of leptin and decreased levels of adiponectin (Table 2).
Novel biomarkers for inﬂammatory and oxidative stress
were assayed. Individuals with MetS showed most signiﬁcant
increases in ox-LDL (P<. 0001) & hsCRP (P<. 0001),
although sPLA2 (P = .028), IL-6 (P = .039) and neopterin
(P = .036) levels were also signiﬁcantly increased (Table 3).
3.2. Prediction of MetS Incidence Using Markers of Inﬂam-
mation and Oxidative Stress. We used multinomial logistic
regression analysis to identify biomarkers that classify sub-
jects with risk of developing MetS. The study population was
divided into 4 groups as follows: group 1—subjects without
MetS (as deﬁned by the modiﬁed ATP-III guidelines) and
CAD; group 2—subjects with MetS and no CAD, group 3—
subjects without MetS and CAD aﬀected, and group 4—
subjects with MetS and CAD aﬀected. This study design
could indicate biomarkers with a speciﬁc role in MetS by
comparing groups 1 and 2 while CAD-speciﬁc markers
would be obtained by comparing groups 1 and 3. Of the
four inﬂammatory markers studied, only hsCRP identiﬁed
subjects with risk of developing MetS (OR 1.492 95% CI
1.144–1.947; P = .003) (Table 4(a)). Among the oxidative
stress markers, oxLDL best predicted MetS in our population
(OR6.03195%CI2.856–12.740;P<. 0001).IL-6emergedas
a CAD-speciﬁc marker and neopterin seemed to be a marker
for subjects with both MetS and CAD (Table 4(b)).
Having identiﬁed the key markers, we performed logistic
regression analysis to assess the interaction between these
markers. Using both forward and backward logistic regres-
sion analysis, we found that all the three markers qualiﬁed
for the model indicating that they independently predict
risk of developing MetS. The odds ratio for development of
MetS was highest for oxLDL (OR 4.956 95% CI 2.504–9.810;
P<. 0001) compared to hsCRP (OR 1.324 95% CI 1.070–
1.638;P = .010).IncombinationwithoxLDLandhsCRPthe
odds of prediction of developing MetSwasnot signiﬁcantfor4 Cardiology Research and Practice
Table 2: Clinical and demographic characteristics of the study subjects.
Individuals with MetS Individuals without MetS P-Value
(n = 968) (n = 1348)
CAD individuals (n) (%) 388 (40.1%) 385 (28.6%) <.0001
Continuous variables—Mean ± SEM (retransformed mean)
Age 51.689 ± 1.102 48.309 ± 1.209 .864
BMI (kg/M2) 26.855 ± 0.383 25.036 ± 0.420 <.0001
Waist hip ratio 0.937 ± 0.006 0.918 ± 0.007 .372
Systolic blood pressure 129.326 ± 1.305 121.296 ± 1.432 <.0001
Diastolic blood pressure 84.838 ± 0.760 79.184 ± 0.834 <.0001
Total cholesterol mg/dL∗ 5.148 ± 0.021 (172.0869) 5.039 ± 0.023 (154.3156) .004
Triglycerides mg/dL∗ 5.171 ± 0.036 (176.0908) 4.708 ± 0.039 (110.830) <.0001
HDL-Cholesterol mg/dL∗ 3.591 ± 0.020 (36.2703) 3.762 ± 0.022 (43.0344) <.0001
LDL-Cholesterol mg/dL∗ 4.550 ±0.034 (94.6324) 4.417 ± 0.037 (82.8473) .051
Adiponectin ng/ml (n = 766) 8.308 ± 0.034 (4056.1924) 8.542 ± 0.038 (5125.5852) .000
Leptin ng/ml (n = 543) 2.888 ± 0.070 (17.9573) 2.490 ± 0.090 (12.0612) .001
Categorical Variables: n (%)
Male 552 (57.0) 802 (59.5) .226
Female 416 (43.0) 545 (40.5)
Smoking
Never 745 (77.3) 1076 (80.1)
.318 Ex-Smoker 138 (14.3) 164 (12.2)
Occasional 11 (1.1) 19 (1.4)
Current Smoker 70 (7.3) 85 (6.3)
Hypertension 383 (39.6) 301 (22.4) <.0001
Diabetes 313 (32.4) 196 (14.6) <.0001
Statin 279 (29.3) 294 (22.0) <.0001
∗Log transformed variables represented as Mean ± Standard error (retransformed mean). P-value for categorical values was obtained using chi-square test
and for continuous variables using for 2-sample t-test.
Table 3: Comparison of plasma levels of inﬂammatory and oxidative stress markers among subjects with and without metabolic syndrome.
Variable Individuals with MetS Individuals without MetS P-value
Mean ± SEM (retransformed mean)
sPLA2 (pg/ml) 8.119 ± 0.046 (3357.6614) 7.963 ± 0.054 (2872.6780) .028∗
Interleukin 6 (pg/ml) 1.151 ± 0.064 (3.1613) 0.945 ± 0.076 (2.5728) .039∗
Myeloperoxidase (μg/L) 5.591 ± 0.042 (268.0034) 5.614 ± 0.049 (274.2390) .723
Neopterin (nmol/L) 2.142 ± 0.038 (8.5164) 2.020 ± 0.044 (7.5383) .036∗
Fibrinogen (g/L) 1.468 ± 0.019 (4.3405) 1.431 ± 0.023 (4.1828) .216
oxLDL (mU/L) 10.971 ± 0.027 (58162.72706) 10.789 ± 0.032 (48484.52724) <.0001∗∗
hsCRP (μg/ml) 1.024 ± 0.091 (2.7843) 0.515 ± 0.107 (1.6736) <.0001∗∗
neopterin (P = .180) (Figure 1). ROC curve analysis using
the predictive probability for the above model evaluated the
utility of assaying oxLDL, hsCRP and neopterin for risk
prediction. When all 3 markers were used in combination,
the AUC of the model was 0.71 (P<. 0001) indicating that
71% of the study population could be classiﬁed correctly
based on these markers (Figure 2).
3.3. Discriminant Analysis. To assess the percent contribu-
tion of the inﬂammatory and oxidative stress biomarkers
to identify individuals with MetS we conducted linear
discriminant analysis. As seen in Table 5(a), among all
biomarkers studied, the structure correlation for ox-LDL
is the highest (0.746) with a max contribution (37.99%)
to a diagnosis of MetS. Based on the Discriminant scores
obtained, we could classify 63.4% of the subjects correctly.
We obtained threshold levels for these biomarkers for
the detection of MetS based on the Discriminant scores
(Table 5(b)). Subjects with higher than the threshold value
for ox-LDL have a 5-fold risk of developing MetS. Table 5(c)
depicts the mean levels of these biomarkers obtained for
the four groups based on the predictive classiﬁcation.Cardiology Research and Practice 5
Table 4
(a) Multinominal regression analysis: Odds ratio and 95% CI for inﬂammatory and oxidative stress markers for subjects with and without MetS
OR (95% CI) P-value
Inﬂammatory markers
sPLA2 0.967 (0.64–1.455) .874
Interleukin 6 1.298 (0.934–1.804) .120
hsCRP 1.492 (1.144–1.947) .003∗∗
Fibrinogen 0.525 (0.168–1.634) .266
Oxidative stress markers
Myeloperoxidase 1.262 (0.810–1.969) .304
Neopterin 2.934 (1.809–4.758) <.0001∗∗
oxLDL 6.031 (2.856–12.740) <.0001∗∗
Reference category: individuals without MetS and without CAD.
(b) Multinominal regression analysis: odds ratio and 95% CI for various inﬂammatory and oxidative stress markers for subjects with MetS and CAD
OR (95% CI) P-value
Inﬂammatory markers
sPLA2 0.670 (0.435–1.030) .068
Interleukin 6 4.716 (3.120–7.130) <.0001∗∗
hsCRP 0.967 (0.738–1.268) .810
Fibrinogen 0.313 (0.102–0.964) .043∗
Oxidative stress markers
Myeloperoxidase 1.842 (1.105–3.072) .019∗
Neopterin 6.209 (3.549–10.864) <.0001∗∗
oxLDL 2.992 (1.327–6.747) .008∗∗
Reference category: individuals without MetS and without CAD.
0 2 4 68 10 12 14
oxLDL
Neopterin
hsCRP
OR = 4.956,
OR = 1.416,
P = .18
OR = 1.324,
P = .01
P = .000
Odds ratio
Figure 1: Error bar plot showing the odds ratio and 95% CI for
hsCRP, neopterin and oxLDL towards risk of developing metabolic
syndrome.
As expected, mean levels of these markers were signiﬁcantly
diﬀerent between groups 1 (without MetS) and 2 (with
MetS) indicating the importance of these 3 biomarkers in
identifying subjects at risk of MetS.
4. Discussion
Increased oxidative stress and inﬂammatory biomarkers are
known to play an important role in the initiation and
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Figure 2: Area under the ROC curve for prediction of metabolic
syndrome using a combination of three biomarkers viz oxLDL,
hsCRP and neopterin
progression of atherosclerotic vascular disease [17, 18],
a major cause of morbidity and mortality in the world [19].
The presence of vascular risk factors led to the identiﬁcation
of a unique pathophysiological condition called metabolic6 Cardiology Research and Practice
Table 5
(a) Discriminant analysis results
Structure matrix
Function Contribution (%)
1
Ln oxLDL .746 37.99
Ln HsCRP .639 27.87
Ln Neopterin .522 18.59
Ln sPLA2 .411 11.53
Ln Interleukin6 .242 3.99
(b) Threshold levels for the biomarkers obtained using Dis-
criminant score
oxLDL 39922.68mU/L
hsCRP 4.00μg/ml
Neopterin 7.0596nmol/L
63.4% of cases were correctly classiﬁed using discriminant
analysis.
(c) Mean levels of biomarkers for discriminant groups
Variables
Discriminant
group
(see Table 5(d))
Mean ± S.E
(retransformed mean)
P-value for group
diﬀerences
hsCRP (μg/ml)
1 −0.066 ±0.080 (0.9361) <.0001∗∗
21 .240 ±0.102 (3.4556)
30 .393 ±0.128 (1.4814) <.0001∗∗
41 .219 ±0.092 (3.3838)
OxLDL (mU/L)
11 0 .623 ±0.022 (41068.6362) <.0001∗∗
21 1 .005 ±0.028 (60174.2621)
31 0 .682 ±0.036 (43564.5924) <.0001∗∗
41 1 .106 ±0.026 (66569.3806)
Neopterin (nmol/L)
11 .766 ±0.035 (5.8474) <.0001∗∗
22 .231 ±0.045 (9.3091)
31 .896 ±0.056 (6.6592) <.0001∗∗
42 .223 ±0.040 (9.2349)
(d) Discriminant groups
Actual group Predicted group Discriminant group
Unaﬀected Unaﬀected 1
Unaﬀected Aﬀected 2
Aﬀected Unaﬀected 3
Aﬀected Aﬀected 4
syndrome [1], now known to be characterized by elevated
inﬂammatorymarkersandincreasedoxidativestressthatcan
predict cardiovascular events such as the risk of myocardial
infarction, stroke, and peripheral arterial disease [6, 20–22].
Importantly, the risk for Coronary Heart Disease (CHD) is
markedly greater in obese individuals with MetS compared
with those without it [23, 24]. However, the association
and eﬀe c to fM e t So np l a s m ab i o m a r k e r so fi n ﬂ a m m a t i o n
and oxidative stress is largely unknown. In this study we
tested our hypothesis that markers of inﬂammation and
oxidative stress can diﬀerentiate between individuals with
or without MetS. We also studied the individual ability of
these biomarkers in predicting MetS in an otherwise healthy
person.
In this ﬁrst report looking at the contribution of
inﬂammatory markers to MetS in Asian Indians from India,
we ﬁnd that MetS enhances inﬂammatory and oxidative
stress and found signiﬁcantly higher circulating levels of
oxLDL, hsCRP, sPLA2, IL-6 and neopterin in subjects
with MetS compared to those without. These ﬁndings areCardiology Research and Practice 7
consistent with contemporary data [20–23]. To identify
biomarkers with potential to diagnose MetS, we divided the
study cohort into 4 groups: with/without MetS and those
with/without CAD. This was done to identify novel plasma
biomarkersspeciﬁcallyassociatedwithMetS(Table 4(a))and
CAD (Table 4(b)). Multinomial logistic regression analysis
of these groups of subjects revealed that among all the
inﬂammatory biomarkers and markers of oxidative stress
studied, hsCRP and oxLDL identiﬁed individuals with risk
of developing MetS. IL-6 was the best marker of CAD risk
and neopterin identiﬁed subjects with both CAD and MetS.
Further analysis revealed that of the three markers only
hsCRP and oxLDL identiﬁed individuals with MetS and
oxLDListhebestpredictorofMetS.Thiswasdespitethelack
oflargevariationsinoxLDLlevelsbetweenCADaﬀectedand
unaﬀected groups in the study cohort.
OxLDL is known to be a potent inducer of (a) foam
cells, that make a hallmark of atherosclerosis-fatty streaks,
and (b) systemic inﬂammation alongside propagation of
atherosclerosis [12, 14, 17, 25]. This may explain our robust
ﬁndings with respect to this biomarker.
ROC curve analysis using predictive probability models
revealed that a combination of oxLDL, hsCRP and neopterin
identiﬁes 71% of individuals with MetS. Discriminant
analysis revealed the percent contribution of each of the
biomarkers studied towards MetS. OxLDL contributed max-
imally and on the basis of the discriminant scores 63.4%
of the cohort was classiﬁed accurately (Table 5(a)). Having
obtained threshold values of ox-LDL for recognition of MetS
using discriminant score, we found that subjects with higher
values showed a 5-fold greater risk of developing MetS. The
propensity of the LDL particles for oxidation decides the
concentration of oxidized LDL in circulation. Small dense
LDL contains fewer anti-oxidants, and therefore is more
prone to oxidation [14]. MetS has been reported to be
associated with a higher prevalence of small dense LDL [26]
and among ethnic groups, Asian Indians are reported to
show higher levels of small dense LDL particles [27, 28].
As found in our research, the fact that people with MetS
are at an increased risk of macro vascular disease and death
[29] appears to further explain the strong association of
MetS with high concentrations of oxLDL. Our ﬁndings are
concurrent with studies in various populations [14, 30–
32], but this is the ﬁrst report on Asian Indians from
India.
Inconclusion,ourpopulationdatafromfamiliesofAsian
Indians with strong family histories of CAD shows that
metabolic syndrome is associated with high inﬂammatory
and oxidative stress. Diagnosis of MetS adds weight to the
comprehensive CAD risk assessment of individuals. Further,
novel biomarkers oxLDL, hsCRP and neopterin can be
utilized to identify people with MetS in the Asian Indian
population. OxLDL has been identiﬁed as the best predictive
biomarker for MetS in Asian Indians and contributes
maximally to the dysmetabolic state in comparison to all
other biomarkers. Further research will validate its use to
diagnose people with MetS compared to internationally
deﬁnedcriteriatoultimatelyyieldacost-eﬀectivemethodfor
MetS diagnosis and CAD risk stratiﬁcation.
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